Karyopharm reports second quarter 2022 financial results and highlights recent company progress

– achieved second quarter 2022 total revenue of $39.7 million, up 76% versus second quarter 2021; xpovio® (selinexor) net product revenue of $29.0 million, a 44% increase over q2 2021 – –  received  full marketing authorization from the european commission expanding indication for nexpovio® (selinexor) for treatment of adults with multiple myeloma who have received at least one prior therapy – – clinical updates from phase 1/2 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis and interim data from phase 2 study evaluating eltanexor in relapsed/refractory mds expected in 2h 2022 – – company provides full year 2022 total revenue guidance of $155 million to $165 million including revised xpovio net product revenue of $120 million to $130 million and non-gaap r&d and sg&a expense guidance of $250 million to $265 million; re-iterates cash runway to early 2024 – – conference call scheduled for today at 8:00 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking